PMC7265239_01
a OCT image demonstrating hiperrrfective changes on the choroid secondary to the nevus and also several drusen (arrowheads) over and temporal do the lesion. b Color fundus photograph showing the presence of nevus. c Fluorescein angiography and d indocyanine green reveals areas of hyperfluorescence (blue arrow) corresponding to polypoidal vasculopathy and an area of hypofluorescence (red arrowhead) corresponding to the choroidal nevus. The yellow rectangle shows foveal OCT images demonstrating. e the presence of retinal pigmental epithelium detachment in the first visit f its worsening after 14 months of follow-up and g its remodeling after 1 month of treatment with 2 monthly-bevacizumab injections
40942_2020_223_Fig1_HTML.jpg
PMC7265239_01_40942_2020_223_Fig1_HTML.jpg
Fig1
OCT showed regression of PCV and PED after two treatments, visual acuity improved to 20/20 (LogMAR 0) OS. (Figure 1).
PMC7265239_02
a Color fundus photo shows an elevated hypechromic lesion consistent with a choroidal nevus. b Fluorescein angiography shows an area of peripapillary hyperfluorescence. c Indocyanine green angiography shows a hot spot (red arrow). Bottom: d OCT images demonstrating the presence of subretinal fluid in the first visit and e shows the response after 1 month of one ranibizumab intravitreal injection
40942_2020_223_Fig2_HTML.jpg
PMC7265239_02_40942_2020_223_Fig2_HTML.jpg
Fig2
The patient returned for a follow-up visit showing vision improvement to LogMAR 0,1(20/25) and resolution of subretinal fluid (Fig. 2).
PMC7265239_03
a Color fundus photo shows an elevated melanocytic choroidal lesion consistent with a nevus. b Fluorescein angiography shows an area of hyperfluorescence on the surface of the nevus. c Similarly, indocyanine green angiography shows a hot spot (red arrowhead) on the nevus' surface corresponding (PCV). Bottom: d OCT images demonstrating the presence of subretinal fluid and loss of integrity of internal retinal layers in the first visit and e shows the treatment response after 1 month of 3 monthly-bevacizumab intravitreal injections
40942_2020_223_Fig3_HTML.jpg
PMC7265239_03_40942_2020_223_Fig3_HTML.jpg
Fig3
The patient showed substantial response with vision improving to LogMAR 0(20/20) and resolution of subretinal fluid (Fig. 3).